LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Alcon Inc

Geschlossen

BrancheGesundheitswesen

87.92 1.37

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

86.77

Max

88.04

Schlüsselkennzahlen

By Trading Economics

Einkommen

76M

350M

Verkäufe

-29M

2.5B

KGV

Branchendurchschnitt

37.853

51.198

EPS

0.73

Dividendenrendite

0.39

Gewinnspanne

14.153

Angestellte

25,000

EBITDA

-226M

463M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+25.24% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.39%

2.40%

Nächstes Ergebnis

19. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.1B

42B

Vorheriger Eröffnungskurs

86.55

Vorheriger Schlusskurs

87.92

Nachrichtenstimmung

By Acuity

34%

66%

95 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Alcon Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Mai 2025, 15:56 UTC

Ergebnisse
Wichtige Markttreiber

Alcon Shares Fall After Lowering 2025 Outlook

26. März 2025, 21:22 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

24. März 2025, 12:36 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon to Buy Lensar in Deal Worth Up to $430 Million

30. Mai 2025, 06:32 UTC

Market Talk
Ergebnisse

Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk

22. Mai 2025, 20:46 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

13. Mai 2025, 20:32 UTC

Ergebnisse

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13. Mai 2025, 20:31 UTC

Ergebnisse

Alcon 1Q Sales $2.45B >ALC.EB

13. Mai 2025, 20:30 UTC

Ergebnisse

Alcon 1Q Rev $2.47B >ALC.EB

13. Mai 2025, 20:30 UTC

Ergebnisse

Alcon 1Q EPS 70c >ALC.EB

8. Apr. 2025, 08:20 UTC

Market Talk

Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk

26. März 2025, 21:55 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

26. März 2025, 20:33 UTC

Akquisitionen, Fusionen, Übernahmen

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

26. März 2025, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

26. März 2025, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

26. März 2025, 20:31 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

26. März 2025, 20:31 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Inc. Unit Alcon Research Previously Sued Aurion to Prevent It From Going Public

26. März 2025, 20:31 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Acquires Majority Interest in Aurion Biotech >ALC.EB

26. März 2025, 20:30 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Acquires Majority Interest in Aurion Biotech

24. März 2025, 12:21 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon to Buy Lensar in Deal Worth Up to $430M

24. März 2025, 12:05 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon: Transaction Is Anticipated to Close in Mid-To-Late 2025 >ALC

24. März 2025, 12:05 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon: Transaction Represents a Total Consideration of Up to About $430M >ALC

24. März 2025, 12:04 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon: Additional Non-Tradeable Contingent Value Right Offering Up to $2.75 Per Shr in Cash, Conditioned on Achievement of 614,000 Cumulative Procedures With LENSAR's Products Between Jan 1, 2026, and Dec 31, 2027 >ALC

24. März 2025, 12:04 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Will Purchase All Outstanding Shrs of LENSAR for $14.00 Per Shr in Cash >ALC

24. März 2025, 12:03 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon: Acquisition Includes ALLY Robotic Cataract Laser Treatment System, LENSAR's Proprietary Streamline Software Technology and LENSAR Legacy Laser System >ALC

24. März 2025, 12:03 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Agrees to Acquire LENSAR >ALC

24. März 2025, 12:00 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Agrees To Acquire LENSAR, Inc. >ALC LNSR

25. Feb. 2025, 21:33 UTC

Ergebnisse

Alcon Sees 2025 Adj EPS $3.15-Adj EPS $3.25 >ALC.EB

25. Feb. 2025, 21:33 UTC

Ergebnisse

Alcon Sees 2025 Sales $10.2B-$10.4B >ALC.EB

25. Feb. 2025, 21:32 UTC

Ergebnisse

Alcon: Board Authorized the Repurchase of Up to $750M of the Company's Common Shrs >ALC.EB

25. Feb. 2025, 21:31 UTC

Ergebnisse

Alcon 4Q EPS 57c >ALC.EB

Peer-Vergleich

Kursveränderung

Alcon Inc Prognose

Kursziel

By TipRanks

25.24% Vorteil

12-Monats-Prognose

Durchschnitt 108.87 USD  25.24%

Hoch 123 USD

Tief 90 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Alcon Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

16 ratings

14

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

95.77 / 97.61Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

95 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.